Objectives: To examine metabolic side-effects of year-long treatment with clozapine, risperidone, quetiapine, or olanzapine in comparison to treatment with haloperidol or perphenazine, among elderly individuals with long-term schizophrenia. Participants and Methods: In a retrospective chart review, clinical records of 228 psychiatric inpatients with persistent schizophrenia were examined to determine any differences in metabolic side-effects of typical versus atypical antipsychotic treatment. Results: There were no significant differences with respect to body mass index, body weight, blood glucose, and serum triglyceride, cholesterol, B12, and folic acid levels. Conclusions: Elderly psychogeriatric patients may be less susceptible to the metabolic side-effects associated with atypical antipsychotic agents than younger populations. This finding warrants further investigation in prospective randomised controlled trials.
|Number of pages||4|
|Journal||Hong Kong Journal of Psychiatry|
|State||Published - Sep 2009|
- Antipsychotic agents